An online hybrid test was carried out on a 40-story 120-m high concrete shear wall structure. The structure was divided into two substructures whereby a physical model of the bottom three stories was tested in the lab...An online hybrid test was carried out on a 40-story 120-m high concrete shear wall structure. The structure was divided into two substructures whereby a physical model of the bottom three stories was tested in the laboratory and the upper 37 stories were simulated numerically using ABAQUS. An overlapping domain method was employed for the bottom three stories to ensure the validity of the boundary conditions of the superstructure. Mixed control was adopted in the test. Displacement control was used to apply the horizontal displacement, while two controlled force actuators were applied to simulate the overturning moment, which is very large and cannot be ignored in the substructure hybrid test of high-rise buildings. A series of tests with earthquake sources of sequentially increasing intensities were carried out. The test results indicate that the proposed hybrid test method is a solution to reproduce the seismic response of high-rise concrete shear wall buildings. The seismic performance of the tested precast high-rise building satisfies the requirements of the Chinese seismic design code.展开更多
Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled...Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and 17 patients completed the study (mean age: 73 years and GOLD I/II/III/IV, 5/10/1/1). The mean CAT scores significantly improved (9.2 to 5.4, p = 0.015) and 10 patients (58.8%) showed ≥2 points improvement, a minimal clinically important difference. The mean FeNO levels significantly decreased from 63.0 to 34.3 ppb (p Conclusions: FeNO-guided treatment with BUD/FM improves symptoms in patients with ACO.展开更多
基金State Key Research Project in 13th Five-Year under Grant No.2016YFC0701901the Beijing Science and Technology Program under Grant No.Z161100001216015the Natural Science Foundation of China under Grants Nos.51422809 and 51778342
文摘An online hybrid test was carried out on a 40-story 120-m high concrete shear wall structure. The structure was divided into two substructures whereby a physical model of the bottom three stories was tested in the laboratory and the upper 37 stories were simulated numerically using ABAQUS. An overlapping domain method was employed for the bottom three stories to ensure the validity of the boundary conditions of the superstructure. Mixed control was adopted in the test. Displacement control was used to apply the horizontal displacement, while two controlled force actuators were applied to simulate the overturning moment, which is very large and cannot be ignored in the substructure hybrid test of high-rise buildings. A series of tests with earthquake sources of sequentially increasing intensities were carried out. The test results indicate that the proposed hybrid test method is a solution to reproduce the seismic response of high-rise concrete shear wall buildings. The seismic performance of the tested precast high-rise building satisfies the requirements of the Chinese seismic design code.
文摘Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and 17 patients completed the study (mean age: 73 years and GOLD I/II/III/IV, 5/10/1/1). The mean CAT scores significantly improved (9.2 to 5.4, p = 0.015) and 10 patients (58.8%) showed ≥2 points improvement, a minimal clinically important difference. The mean FeNO levels significantly decreased from 63.0 to 34.3 ppb (p Conclusions: FeNO-guided treatment with BUD/FM improves symptoms in patients with ACO.
